PBAC's latest decision on Calcipotriol + betamethasone dipropionate: Recommended with restriction (2015). Considered for Chronic stable plaque type psoriasis vulgaris in patients not adequately controlled with either a vitamin D analogue or potent topical corticosteroid monotherapy, specifically for scalp and body treatment.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Adults aged ≥18 years with chronic stable plaque type psoriasis vulgaris not adequately controlled with vitamin D analogue or potent topical corticosteroid monotherapy; patients requiring the 60g strength must require more than 30 grams of product per month.
Therapy area
Dermatology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Other
Pivotal trial size
24 patients
Key trials
PLQ-001, PRO-long, LEO80185-G23, MBL 0202 INT, LEO 80185-G21, MCB 9802 INT, MCB 0003 INT, MCB 9905 INT, LEO 90100-35
Comparator
calcipotriol + betamethasone ointment
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as submission was based on equivalent efficacy and similar safety compared to ointment at the same price.